METHOXSALEN Drug Patent Profile

When do Methoxsalen patents expire, and what generic alternatives are available?

Methoxsalen is a drug marketed by Actavis Inc, Ani Pharms, and Onesource. and is included in three NDAs.

The generic ingredient in METHOXSALEN is methoxsalen. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the methoxsalen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methoxsalen

A generic version of METHOXSALEN was approved as methoxsalen by ONESOURCE on June 5^th, 2014.

Summary for METHOXSALEN

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	26
Patent Applications:	5,874
Drug Prices:	Drug price information for METHOXSALEN
What excipients (inactive ingredients) are in METHOXSALEN?	METHOXSALEN excipients list
DailyMed Link:	METHOXSALEN at DailyMed

See drug prices for METHOXSALEN

Recent Clinical Trials for METHOXSALEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Therakos LLC	PHASE2
Georgetown University	Phase 2
European Organisation for Research and Treatment of Cancer - EORTC	Phase 2

See all METHOXSALEN clinical trials

Pharmacology for METHOXSALEN

Drug Class	Photoactivated Radical Generator Psoralen
Mechanism of Action	Photoabsorption
Physiological Effect	Photosensitizing Activity

Medical Subject Heading (MeSH) Categories for METHOXSALEN

Cross-Linking Reagents

Photosensitizing Agents

Anatomical Therapeutic Chemical (ATC) Classes for METHOXSALEN

D05AD	Psoralens for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

D05BA	Psoralens for systemic use
D05B	ANTIPSORIATICS FOR SYSTEMIC USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for METHOXSALEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Inc	METHOXSALEN	methoxsalen	CAPSULE;ORAL	202603-001	Jun 9, 2015		DISCN	No	No
Ani Pharms	METHOXSALEN	methoxsalen	CAPSULE;ORAL	087781-001	Jun 8, 1982		DISCN	No	No
Onesource	METHOXSALEN	methoxsalen	CAPSULE;ORAL	202687-001	Jun 5, 2014	AB	RX	No	No

Methoxsalen Market Dynamics and Financial Trajectory

Last updated: September 1, 2026

Methoxsalen is a mature, niche photochemotherapy drug with two commercial roles: oral methoxsalen for PUVA treatment of psoriasis and vitiligo, and injectable UVADEX for extracorporeal photopheresis. The oral market is largely generic, fragmented and exposed to supply constraints. UVADEX has greater commercial defensibility because it is tied to the Therakos photopheresis platform, specialized treatment centers and regulatory know-how.

Public filings do not disclose a standalone global methoxsalen market size or product-level revenue forecast. Financial value is concentrated in the photopheresis ecosystem rather than in the active ingredient itself. The strongest commercial factors are recurring treatment demand, installed photopheresis equipment, reimbursement and supply reliability.

What is methoxsalen used for?

Methoxsalen, also known as 8-methoxypsoralen or 8-MOP, increases skin sensitivity to long-wave ultraviolet A radiation. Its approved and established uses depend on the dosage form.

Product or use	Dosage form	Principal indication	Commercial position
Oral methoxsalen, historically marketed as Oxsoralen-Ultra	10 mg capsules	PUVA treatment of severe psoriasis and vitiligo	Mature, generic-exposed market
UVADEX	20 mcg/mL sterile solution	Extracorporeal photopheresis for cutaneous T-cell lymphoma	Specialty product linked to photopheresis systems
Compounded methoxsalen	Capsules or topical preparations	Dermatology and phototherapy uses	Variable regulatory and reimbursement status
Hospital photopheresis use	Injectable methoxsalen plus device procedure	Immunomodulatory treatment, including graft-versus-host disease and other off-label uses	Procedure-driven demand

UVADEX is administered during extracorporeal photopheresis. Patient blood is withdrawn, separated, treated with methoxsalen and UVA light, then returned to the patient. FDA labeling identifies UVADEX for use with the UVAR XTS or CELLEX Photopheresis Systems in patients with cutaneous T-cell lymphoma who have not responded adequately to other treatments.[1]

How large is the methoxsalen market?

The global methoxsalen market is small relative to mainstream dermatology and oncology drugs. Demand is divided between low-value oral or compounded products and higher-value specialty photopheresis treatment.

The market has four structural characteristics:

1. The active ingredient is old and chemically simple.
2. The oral product has limited differentiation and weak pricing power.
3. UVADEX benefits from integration with a regulated device and clinical workflow.
4. Treatment revenue is often captured through the photopheresis procedure rather than reported as methoxsalen product revenue.

The commercial market therefore cannot be assessed by active-ingredient volume alone. A small quantity of UVADEX can support a much larger procedure-based revenue stream involving equipment, disposables, nursing time and hospital reimbursement.

Demand drivers

Demand is supported by:

• Continued diagnosis and treatment of cutaneous T-cell lymphoma.
• Expansion of specialized photopheresis centers.
• Use of extracorporeal photopheresis in graft-versus-host disease, solid-organ transplant rejection and other immune-mediated conditions.
• Long treatment courses requiring repeated procedures.
• Limited substitution within established photopheresis protocols.

The main constraint is that photopheresis is resource-intensive. It requires trained personnel, specialized equipment and treatment-center access. That limits adoption outside tertiary hospitals.

What is the financial trajectory for methoxsalen products?

Methoxsalen has a bifurcated financial trajectory.

The oral segment is mature to declining in value. Generic competition, low unit prices, historical product discontinuations and limited clinical innovation constrain revenue growth. Oral PUVA also faces competition from narrowband UVB, biologics for psoriasis and topical or systemic therapies for vitiligo.

UVADEX has a more durable specialty trajectory. Its economics are supported by recurring use, a specialized delivery system and clinical dependence on photopheresis infrastructure. Growth is more likely to come from procedure volumes, geographic expansion and new photopheresis indications than from higher methoxsalen pricing.

Segment	Revenue direction	Margin profile	Principal risk
Oral methoxsalen	Flat to declining	Low to moderate	Generic pricing and supply disruption
Compounded methoxsalen	Fragmented	Variable	Regulatory and quality controls
UVADEX	Stable to growing in specialty settings	Higher than oral products	Reimbursement, device dependence and procurement
Photopheresis platform	Potentially growing	Specialty-device economics	Capital budgets and clinical adoption

Public company reports generally do not isolate methoxsalen revenue from the broader photopheresis franchise. Mallinckrodt has historically reported Therakos as a specialty business encompassing UVADEX, photopheresis systems and related products, rather than providing a separate UVADEX income statement.[2] As a result, product-level sales, gross margin and operating profit cannot be reliably extracted from public filings.

Which companies commercialize methoxsalen?

The principal commercial entity associated with UVADEX and extracorporeal photopheresis has been Therakos, a Mallinckrodt specialty business. The relevant commercial asset is not only the methoxsalen solution. It includes:

• UVADEX drug supply.
• CELLEX and related photopheresis systems.
• Disposable treatment kits.
• Technical service.
• Clinical training.
• Hospital contracting and reimbursement support.

The oral market has historically included branded and generic suppliers. Brand availability has changed over time, and supply has been less consistent than for major generic drugs. Pharmacy and hospital purchasing channels may rely on different manufacturers or compounding sources depending on formulation and jurisdiction.

Licensing and transaction dynamics

The commercial value of methoxsalen has been linked to ownership of the delivery platform rather than to licensing of the molecule. The drug itself has been known for decades, so meaningful transaction value is more likely to arise from:

• Photopheresis device portfolios.
• Hospital contracts.
• Manufacturing capacity.
• Regulatory approvals.
• Distribution rights.
• Indication expansion.
• Procedure reimbursement.

A transaction involving Therakos would therefore have greater financial significance than a conventional generic methoxsalen license. Public filings have not established a standalone valuation for UVADEX.

What patents protect methoxsalen?

The core methoxsalen molecule is not commercially protected by a live composition-of-matter patent in the United States. It is an old psoralen compound, and any original compound protection expired many years ago.

The remaining intellectual-property value is more likely to arise from:

• Photopheresis apparatus design.
• Disposable tubing and treatment kits.
• Device control systems.
• Manufacturing processes.
• Sterile formulations.
• Packaging and stability.
• Treatment protocols.
• Trademarks and brand recognition.

The Orange Book is the primary FDA source for patents and regulatory exclusivity associated with approved drug products.[3] Methoxsalen’s commercial position does not depend on a conventional long-dated pharmaceutical patent estate. The absence of meaningful molecule-level patent protection increases generic entry risk for oral products.

Are there formulation patents for methoxsalen?

Formulation protection can be relevant to sterile injectable methoxsalen because the product must meet requirements for concentration, stability, sterility and compatibility with photopheresis equipment. Those technical attributes may support manufacturing know-how and regulatory barriers even when patent protection is weak or expired.

A formulation patent would not necessarily prevent competing oral methoxsalen products. Conversely, a device or disposable patent may protect the photopheresis system without blocking manufacture of the active ingredient.

The most durable barrier is operational integration. A competitor would need to establish a compliant sterile product, secure regulatory approval, qualify the product for a photopheresis system and obtain hospital adoption.

What is the FDA regulatory status of methoxsalen?

UVADEX is an FDA-approved prescription product for extracorporeal photopheresis in cutaneous T-cell lymphoma.[1] Its label specifies administration through approved photopheresis systems, which limits the practical substitutability of ordinary oral or compounded methoxsalen.

Oxsoralen-Ultra was approved as an oral methoxsalen product for PUVA treatment. The oral product’s commercial availability has been less stable than its historical regulatory status. FDA drug databases distinguish between approval, marketing status and current commercial availability. A product may remain associated with an approved application while being unavailable from the original manufacturer.

Methoxsalen does not have biosimilar exposure because it is a small-molecule drug. The relevant competitive pathways are:

• Abbreviated New Drug Applications for generic oral products.
• Potential abbreviated applications for injectable products.
• Drug-master-file-supported manufacturing.
• Compounding, subject to applicable federal and state requirements.
• Device-plus-drug competition in photopheresis.

When does methoxsalen lose exclusivity?

Methoxsalen’s principal exclusivity loss occurred long ago. There is no commercially meaningful remaining new-molecule exclusivity period for the active ingredient.

Protection category	Current commercial implication
Original compound patent	Expired
New chemical entity exclusivity	Expired
Oral product exclusivity	Generic competition permitted
UVADEX product protection	Depends more on regulatory history, manufacturing and platform integration
Device patents	May remain relevant by product and jurisdiction
Trade secrets	Potentially important for sterile manufacturing and device compatibility
Trademarks	Protect branding, not the active ingredient

No standard blockbuster-style patent cliff is expected. The market is already in the post-exclusivity phase. Commercial changes will come from supply events, reimbursement revisions, manufacturing transfers and ownership changes rather than from a single patent expiration date.

Are there Paragraph IV challenges to methoxsalen?

Paragraph IV litigation is not a central current risk for the oral methoxsalen market because the relevant products are old and genericized. Any ANDA applicant could challenge listed patents by certifying that a patent is invalid, unenforceable or not infringed. The practical importance of such litigation depends on whether the reference product has active, Orange Book-listed patents.

For UVADEX, competition is more difficult to assess through Paragraph IV activity because the product is linked to a specialized delivery system and treatment procedure. A competitor would need to address both drug approval and practical use within photopheresis workflows.

The principal generic-launch scenarios are:

1. A new oral generic enters and competes mainly on availability and price.
2. A sterile injectable competitor seeks approval and hospital contracts.
3. A hospital or compounding pharmacy uses an alternative source where legally permissible.
4. A competing photopheresis platform gains approval and supplies its own methoxsalen product.
5. Existing platform protection and switching costs delay adoption of a competing system.

What patent litigation affects methoxsalen?

Methoxsalen is not associated with the type of active, high-value patent litigation seen in newer oncology or immunology drugs. Litigation risk is more likely to involve:

• Device patents.
• Disposable treatment kits.
• Contract disputes.
• Manufacturing and supply agreements.
• Trade secrets.
• Product liability.
• Reimbursement and coverage disputes.

The litigation profile is therefore operational rather than molecule-centric. A competitor could avoid direct patent infringement while still facing substantial regulatory and commercial barriers.

What generic entry risks exist for methoxsalen?

Oral methoxsalen

Generic entry risk is high. The product is old, the clinical technology is established and physicians generally have little reason to prefer a premium-priced oral formulation. The main commercial risks are price erosion, pharmacy substitution and intermittent supply.

The segment can still experience shortages because low-volume products may have limited manufacturers. A small number of suppliers can make the market vulnerable to manufacturing deviations, raw-material problems or discontinued product lines.

UVADEX

UVADEX has lower immediate substitution risk than oral methoxsalen. Its position is supported by:

• Use within an approved photopheresis protocol.
• Specialized sterile manufacturing.
• Device compatibility.
• Hospital procurement relationships.
• Repeated treatment demand.
• Switching friction for clinicians and patients.

The risk is not zero. A competing methoxsalen product could target the same photopheresis systems, while a competing photopheresis platform could bundle a drug product with its device.

How does methoxsalen compare with competing treatments?

Treatment	Main use	Advantage over methoxsalen	Limitation
Narrowband UVB	Psoriasis and vitiligo	Less reliance on systemic psoralen	Not equivalent for every patient
Biologics	Moderate-to-severe psoriasis	High efficacy and convenience	Cost, injections and immune effects
Topical vitiligo therapies	Vitiligo	Local administration	Limited for extensive disease
Systemic immunosuppressants	CTCL and immune disorders	Broader disease control	Safety and monitoring burden
Extracorporeal photopheresis	CTCL and immune-mediated conditions	Repeatable, non-cytotoxic immunomodulation	Expensive and resource-intensive

Methoxsalen is most defensible when embedded in extracorporeal photopheresis. It is less defensible as a standalone dermatology product.

What geographic markets matter most?

The United States is the most important market for UVADEX because of its specialty-care infrastructure, FDA pathway and concentration of photopheresis centers. Europe and other developed markets also support photopheresis, but approval, reimbursement and hospital purchasing rules vary by country.

Geographic expansion depends on:

• Local approval of methoxsalen and photopheresis systems.
• Availability of trained treatment centers.
• Reimbursement for the procedure.
• Import and sterile-drug requirements.
• Hospital capital expenditure.
• Clinical guidelines and payer policy.

Emerging markets are less attractive for the full photopheresis platform because the equipment and staffing requirements raise treatment costs. Oral methoxsalen may have broader geographic availability but much lower revenue per patient.

What manufacturing and intellectual-property barriers exist?

The active ingredient is relatively straightforward to manufacture, but commercial-grade products require more than chemical synthesis.

For oral products, barriers include:

• Reliable active pharmaceutical ingredient supply.
• Consistent capsule production.
• Stability and packaging controls.
• Bioequivalence.
• Distribution through low-volume channels.

For UVADEX, barriers include:

• Sterile fill-finish capacity.
• Validated concentration and stability.
• Container-closure integrity.
• Compatibility with photopheresis equipment.
• Consistent supply to treatment centers.
• Regulatory documentation and pharmacovigilance.

These barriers can support pricing even in the absence of active composition patents. They do not create unlimited pricing power because hospitals can pursue alternative suppliers and payers can constrain reimbursement.

What is the investment outlook for methoxsalen?

Methoxsalen is unlikely to become a standalone growth asset comparable with a novel specialty pharmaceutical. Its investment profile is defensive and platform-dependent.

Positive factors include:

• Established clinical use.
• Recurring demand from photopheresis.
• Limited number of specialized suppliers.
• High switching costs in hospital workflows.
• Potential expansion of extracorporeal photopheresis into immune-mediated diseases.

Negative factors include:

• No meaningful molecule-level exclusivity.
• Small addressable patient population.
• Dependence on specialized centers.
• Reimbursement sensitivity.
• Generic competition in oral products.
• Product-specific manufacturing risk.
• Limited disclosure of standalone financial performance.

Revenue exposure is best analyzed at the level of the photopheresis franchise. Investors should not treat total Therakos or specialty-care revenue as equivalent to methoxsalen revenue. The drug is one component of a broader system that includes devices, disposables, services and procedure economics.

Key Takeaways

• Methoxsalen is a mature, post-exclusivity drug with limited standalone pricing power.
• Oral methoxsalen is highly exposed to generic competition and supply volatility.
• UVADEX has stronger commercial durability because it is integrated with extracorporeal photopheresis.
• The core methoxsalen molecule is not protected by a meaningful active U.S. composition patent.
• Current barriers are regulatory, manufacturing, device compatibility and hospital adoption.
• Paragraph IV litigation and biosimilar competition are not major current drivers.
• Public companies do not generally disclose methoxsalen-only revenue or profit.
• Financial performance depends more on photopheresis procedure growth than on methoxsalen unit volume.
• The principal downside risks are reimbursement pressure, supply interruption and competing photopheresis platforms.
• The principal upside is expansion of photopheresis use in oncology, transplant and immune-mediated disease.

FAQs About Methoxsalen Market and Financial Outlook

Is methoxsalen still commercially available?

Yes. Availability differs by dosage form and country. UVADEX remains the key specialty product in extracorporeal photopheresis, while oral and compounded methoxsalen availability is more variable.

Is methoxsalen a generic drug?

Oral methoxsalen is generally exposed to generic competition. UVADEX is an approved branded sterile product whose commercial position is tied to photopheresis systems and specialized treatment delivery.

Does methoxsalen have biosimilar competition?

No. Methoxsalen is a small-molecule drug. Competition arises through generic drug applications, alternative formulations and competing photopheresis platforms.

Can a competitor manufacture methoxsalen for photopheresis?

A competitor would need to satisfy FDA drug requirements, establish sterile manufacturing, demonstrate product quality and address compatibility with the relevant photopheresis system. Drug manufacture alone would not guarantee hospital adoption.

Is methoxsalen an attractive licensing asset?

As a standalone molecule, methoxsalen has limited licensing value. Its stronger strategic value lies in combination with photopheresis devices, sterile manufacturing capacity, hospital contracts or new clinical indications.

References

1. U.S. Food and Drug Administration. (2016). UVADEX methoxsalen injection prescribing information.
2. Mallinckrodt plc. (2023). Annual report for the fiscal year ended December 29, 2023.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.
5. National Cancer Institute. (n.d.). Photopheresis and cutaneous T-cell lymphoma treatment information.